Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCEÂ® (palbociclib), for Patients with Hormone ReceptorâPositive Early Breast Cancer